SecBot SecBot
SECBOTREPLAY Home › Report › DNTH

DNTH · Dianthus Therapeutics reported Q3 2026 net loss of $46.6M ($0.81 per…

Dianthus Therapeutics, Inc. · PRESS-RELEASE filed Nov 4, 2026 at 16:01 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Nov 4, 2026 at 16:01 ET

Dianthus Therapeutics reported Q3 2026 net loss of $46.6M ($0.81 per share), wider than the $36.8M loss in Q3 2025, but the EPS of -$0.81 beat the consensus estimate of -$0.95. The company highlighted strong clinical progress across its pipeline, including a 75% response rate in the CIDP Phase 3 CAPTIVATE trial interim analysis and a $1.2B cash runway into 2030.

  • Q3 2026 net loss of $46.6M ($0.81 per share) vs $36.8M ($0.97 per share) in Q3 2025
  • EPS of -$0.81 beat consensus estimate of -$0.95
  • Revenue of $1.21M (license revenue) vs $396K in Q3 2025, well above $389K consensus
  • Cash, cash equivalents and investments of ~$1.2B as of Sep 30, 2026, providing runway into 2030

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access